Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
- Bryn Mawr Hospital — Bryn Mawr, Pennsylvania
- Christiana Care Health System-Concord Health Center — Chadds Ford, Pennsylvania
- Chambersburg Hospital — Chambersburg, Pennsylvania
Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Pennsylvania: - Saint Luke's Cancer Center - Allentown — Allentown, Pennsylvania
- Saint Luke's University Hospital-Bethlehem Campus — Bethlehem, Pennsylvania
- Crozer-Keystone Regional Cancer Center at Broomall — Broomall, Pennsylvania
- Christiana Care Health System-Concord Health Center — Chadds Ford, Pennsylvania
- Chambersburg Hospital — Chambersburg, Pennsylvania
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Pennsylvania: - UPMC-Heritage Valley Health System Beaver — Beaver, Pennsylvania
- UPMC Hillman Cancer Center at Butler Health System — Butler, Pennsylvania
- Christiana Care Health System-Concord Health Center — Chadds Ford, Pennsylvania
- WellSpan Medical Oncology and Hematology — Chambersburg, Pennsylvania
- UPMC Hillman Cancer Center - Passavant - Cranberry — Cranberry Township, Pennsylvania
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Pennsylvania: - Saint Luke's Cancer Center - Allentown — Allentown, Pennsylvania
- Saint Luke's University Hospital-Bethlehem Campus — Bethlehem, Pennsylvania
- Chambersburg Hospital — Chambersburg, Pennsylvania
- Northeast Radiation Oncology Center — Dunmore, Pennsylvania
- Saint Luke's Hospital-Anderson Campus — Easton, Pennsylvania
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Pennsylvania: - Saint Luke's University Hospital — Bethlehem, Pennsylvania
- Lancaster General Health — Lancaster, Pennsylvania
- University of Pennsylvania Abramson Cancer Center — Philadelphia, Pennsylvania
- UPMC Magee-Womens Hospital — Pittsburgh, Pennsylvania
- Guthrie Clinical Research — Sayre, Pennsylvania
Phase 3 Recruiting Industry
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in Pennsylvania: - Lehigh Valley Health Network - Cedar Crest — Allen, Pennsylvania
- Consultants In Medical Oncology and Hematology, P.C. — Broomall, Pennsylvania
- Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania
- Holy Redeemer Hospital And Medical Center — Meadowbrook, Pennsylvania
- Alliance Cancer Specialists, PC — Media, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBC…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05827081
Sites in Pennsylvania: - Consultants In Med Onco And Hema — Drexel Hill, Pennsylvania
- Univ of Pittsburg Med Ctr Pinnacle — Harrisburg, Pennsylvania
- Allegheny Health Network — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Pennsylvania: - Research Site — York, Pennsylvania
Phase 3 Recruiting Industry
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in Pennsylvania: - Alliance Cancer Specialists — Bensalem, Pennsylvania
- Ann B. Barshinger Cancer Institute — Lancaster, Pennsylvania
- Abramson Cancer Center; Univ of Pennsylvania; Clinical Research Unit — Philadelphia, Pennsylvania
- WellSpan Oncology Research — York, Pennsylvania
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in Pennsylvania: - UPMC Hillman Cancer Center - Magee-Women?s Hospital — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…
Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in Pennsylvania: - Redeemer Health - Holy Redeemer Hospital — Meadowbrook, Pennsylvania
- Sidney Kimmel Comprehensive Cancer Center - Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
Phase 3 Recruiting Industry
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in Pennsylvania: - Abramson Cancer Center of The University of Pennsylvania — Philadelphia, Pennsylvania
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
Phase 3 Recruiting Industry
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who ha…
Sponsor: LeonaBio
NCT ID: NCT05696626
Sites in Pennsylvania: - University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast …
Sponsor: Celcuity Inc
NCT ID: NCT06757634
Sites in Pennsylvania: - Rittenhouse Hematology/Oncology — Philadelphia, Pennsylvania
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- UPMC Altoona — Altoona, Pennsylvania
- Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
- Bryn Mawr Hospital — Bryn Mawr, Pennsylvania
- Pocono Medical Center — East Stroudsburg, Pennsylvania
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in Pennsylvania: - Alliance Cancer Specialists — Horsham, Pennsylvania
- University of Pennsylvania, Abramson Cancer Center, Perelman Center for Advanced Medicine — Philadelphia, Pennsylvania
- University of Pittsburgh (UPMC) — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Pennsylvania: - Rittenhouse Hematology Oncology — Philadelphia, Pennsylvania
- Thomas Jefferson University — Philadelphia, Pennsylvania
- AHN West Penn Hospital — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…
Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in Pennsylvania: - Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania
Phase 2 Recruiting Academic/Other
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Sponsor: Oana Danciu
NCT ID: NCT05467891
Sites in Pennsylvania: - Penn State Cancer Institute — Hershey, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, seven …
Sponsor: Hoffmann-La Roche
NCT ID: NCT03424005
Sites in Pennsylvania: - Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination…
Sponsor: ORIC Pharmaceuticals
NCT ID: NCT05315700
Sites in Pennsylvania: - University of Pennsylvania — Philadelphia, Pennsylvania
Phase 2 Recruiting Academic/Other
This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT03808337
Sites in Pennsylvania: - Lehigh Valley Health Network — Allentown, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatmen…
Sponsor: Hoffmann-La Roche
NCT ID: NCT04802759
Sites in Pennsylvania: - Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
- University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania
Phase 2 Recruiting Academic/Other
Newly diagnosed post-menopausal women with clinical stage II-III, HR+HER2- breast cancer are eligible to a randomized trial, concurrently open at five US academic institutions. Patients receiving 4 months of standard neoadjuvant hormonal t…
Sponsor: Weill Medical College of Cornell University
NCT ID: NCT03804944
Sites in Pennsylvania: - UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 2 Recruiting Academic/Other
This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: * Learn how well…
Sponsor: SCRI Development Innovations, LLC
NCT ID: NCT05748834
Sites in Pennsylvania: - Alliance Cancer Specialists — Bensalem, Pennsylvania